CHI3L1 (YKL-40) is expressed in human gliomas and regulates the invasion, growth and survival of glioma cells

International Journal of Cancer

Volumn 128, Issue 6, 2011, Pages 1316-1326

  Ku, Bo Mi ^a   Lee, Yeon Kyung ^a   Ryu, Jinhyun ^a   Jeong, Joo Yeon ^a   Choi, Jungil ^a   Eun, Keyoung Mi ^b   Shin, Hye Young ^b   Kim, Dong Gyu ^b   Hwang, Eun Mi ^a   Yoo, Jae Cheal ^a   Park, Jae Yong ^a   Roh, Gu Seob ^a   Kim, Hyun Joon ^a   Cho, Gyeong Jae ^a   Choi, Wan Sung ^a   Paek, Sun Ha ^b   Kang, Sang Soo ^a  

^a Gyeongsang National University School of Medicine   (South Korea)

^b Seoul National University   (South Korea)

Author keywords

CHI3L1; glioblastoma; local invasion; malignant transformation

Indexed keywords

CHITINASE 3 LIKE 1; CISPLATIN; DOXORUBICIN; ETOPOSIDE; GELATINASE A; GLYCOPROTEIN; PROTEIN YKL 40; SHORT HAIRPIN RNA; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER GROWTH; CANCER INVASION; CELL ADHESION; CELL GROWTH; CELL INVASION; CELL SURVIVAL; CELLULAR DISTRIBUTION; CONTROLLED STUDY; DOWN REGULATION; DRUG RESISTANCE; ENZYME ACTIVITY; ENZYME REGULATION; GENE EXPRESSION; GENE FUNCTION; GENE OVEREXPRESSION; GENE TARGETING; GLIOMA; GLIOMA CELL; HUMAN; HUMAN CELL; HUMAN TISSUE; MALIGNANT TRANSFORMATION; MORBIDITY; PRIORITY JOURNAL;

APOPTOSIS; BLOTTING, NORTHERN; BLOTTING, WESTERN; BRAIN NEOPLASMS; CELL ADHESION; CELL MOVEMENT; CELL PROLIFERATION; CELLS, CULTURED; GLIOMA; GLYCOPROTEINS; HUMANS; IMMUNOENZYME TECHNIQUES; LECTINS; NEOPLASM INVASIVENESS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, SMALL INTERFERING; TUMOR CELLS, CULTURED; TUMOR MARKERS, BIOLOGICAL;

EID: 79551491340     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.25466     Document Type: Article

References (41)

1. Nakada M, Nakada S, Demuth T, Tran NL, Hoelzinger DB, Berens ME,. Molecular targets of glioma invasion. Cell Mol Life Sci 2007; 64: 458-78.
2. Giese A, Bjerkvig R, Berens ME, Westphal M,. Cost of migration: invasion of malignant gliomas and implications for treatment. J Clin Oncol 2003; 21: 1624-36.
3. Cayre M, Canoll P, Goldman JE,. Cell migration in the normal and pathological postnatal mammalian brain. Prog Neurobiol 2009; 88: 41-63.
4. Stylli SS, Kaye AH, Lock P,. Invadopodia: at the cutting edge of tumour invasion. J Clin Neurosci 2008; 15: 725-37.
5. Hakala BE, White C, Recklies AD,. Human cartilage gp-39, a major secretory product of articular chondrocytes and synovial cells, is a mammalian member of a chitinase protein family. J Biol Chem 1993; 268: 25803-10.
6. Malinda KM, Ponce L, Kleinman HK, Shackelton LM, Millis AJ,. Gp38k, a protein synthesized by vascular smooth muscle cells, stimulates directional migration of human umbilical vein endothelial cells. Exp Cell Res 1999; 250: 168-73.
7. Nishikawa KC, Millis AJ,. gp38k (CHI3L1) is a novel adhesion and migration factor for vascular cells. Exp Cell Res 2003; 287: 79-87.
8. Recklies AD, White C, Ling H,. The chitinase 3-like protein human cartilage glycoprotein 39 (HC-gp39) stimulates proliferation of human connective-tissue cells and activates both extracellular signal-regulated kinase- and protein kinase B-mediated signaling pathways. Biochem J 2002; 365: 119-26.
9. Cintin C, Johansen JS, Christensen IJ, Price PA, Sørensen S, Nielsen HJ,. High serum YKL-40 level after surgery for colorectal carcinoma is related to short survival. Cancer 2002; 95: 267-74.
10. Diefenbach CS, Shah Z, Iasonos A, Barakat RR, Levine DA, Aghajanian C, Sabbatini P, Hensley ML, Konner J, Tew W, Spriggs D, Fleisher M, et al. Preoperative serum YKL-40 is a marker for detection and prognosis of endometrial cancer. Gynecol Oncol 2007; 104: 435-42.
11. Jensen BV, Johansen JS, Price PA,. High levels of serum HER-2/neu and YKL-40 independently reflect aggressiveness of metastatic breast cancer. Clin Cancer Res 2003; 9: 4423-34.
12. Johansen JS, Brasso K, Iversen P, Teisner B, Garnero P, Price PA, Christensen IJ,. Changes of biochemical markers of bone turnover and YKL-40 following hormonal treatment for metastatic prostate cancer are related to survival. Clin Cancer Res 2007; 13: 3244-9.
13. Junker N, Johansen JS, Andersen CB, Kristjansen PE,. Expression of YKL-40 by peritumoral macrophages in human small cell lung cancer. Lung Cancer 2005; 48: 223-31.
14. Tanwar MK, Gilbert MR, Holland EC,. Gene expression microarray analysis reveals YKL-40 to be a potential serum marker for malignant character in human glioma. Cancer Res 2002; 62: 4364-8.
15. Colin C, Baeza N, Bartoli C, Fina F, Eudes N, Nanni I, Martin PM, Ouafik L, Figarella-Branger D,. Identification of genes differentially expressed in glioblastoma versus pilocytic astrocytoma using suppression subtractive hybridization. Oncogene 2006; 25: 2818-26.
16. Nutt CL, Betensky RA, Brower MA, Batchelor TT, Louis DN, Stemmer-Rachamimov AO,. YKL-40 is a differential diagnostic subtypes of high-grade gliomas. Clin Cancer Res 2005; 11: 2258-64.
17. Pelloski CE, Mahajan A, Maor M, Chang EL, Woo S, Gilbert M, Colman H, Yang H, Ledoux A, Blair H, Passe S, Jenkins RB, et al. YKL-40 expression is associated with poorer response to radiation and shorter overall survival in glioblastoma. Clin Cancer Res 2005; 11: 3326-34.
18. Phillips HS, Kharbanda S, Chen R, Forrest WF, Soriano RH, Wu TD, Misra A, Nigro JM, Colman H, Soroceanu L, Williams PM, Modrusan Z, et al. Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell 2006; 9: 157-73.
19. Lal A, Lash AE, Altschul SF, Velculescu V, Zhang L, McLendon RE, Marra MA, Prange C, Morin PJ, Polyak K, Papadopoulos N, Vogelstein B, et al. A public database for gene expression in human cancers. Cancer Res 1999; 59: 5402-7.
20. Nigro JM, Misra A, Zhang L, Smirnov I, Colman H, Griffin C, Ozburn N, Chen M, Pan E, Koul D, Yung WK, Feuerstein BG, et al. Integrated array-comparative genomic hybridization and expression array profiles identify clinically relevant molecular subtypes of glioblastoma. Cancer Res 2005; 65: 1678-86.
21. Shostak K, Labunskyy V, Dmitrenko V, Malisheva T, Shamayev M, Rozumenko V, Zozulya Y, Zehetner G, Kavsan V,. HC gp-39 gene is upregulated in glioblastomas. Cancer Lett 2003; 198: 203-10.
22. Tso CL, Freije WA, Day A, Chen Z, Merriman B, Perlina A, Lee Y, Dia EQ, Yoshimoto K, Mischel PS, Liau LM, Cloughesy TF, et al. Distinct transcription profiles of primary and secondary glioblastoma subgroups. Cancer Res 2006; 66: 159-67.
23. Lu KV, Jong KA, Rajasekaran AK, Cloughesy TF, Mischel PS,. Upregualtion of tissue inhibitor of metalloproteinases (TIMP)-2 promotes matrix metalloproteinase (MMP)-2 activation and cell invasion in a human glioblastoma cell line. Lab Invest 2004; 84: 8-20.
24. Ridley AJ, Schwartz MA, Burridge K, Ginsberg MH, Borisy G, Parsons JT, Horwitz AR,. Cell migration: integrating signals from front to back. Science 2003; 302: 1704-9.
25. Ridley AJ,. Rho GTPases and cell migration. J Cell Sci 2001; 114: 2713-22.
26. Junker N, Johansen JS, Hansen LT, Lund EL, Kristjansen PE,. Regulation of YKL-40 expression during genotoxic or microenvironmental stress in human glioblastoma cells. Cancer Sci 2005; 96: 183-90.
27. Kroes RA, Dawson G, Moskal JR,. Focused microarray analysis of glycol-gene expression in human glioblastomas. J Neurochem 2007; 103 (Suppl 1): 14-24.
28. Pelloski CE, Lin E, Zhang L, Yung WK, Colman H, Liu JL, Woo SY, Heimberger AB, Suki D, Prados M, Chang S, Barker FG, III, et al. Prognostic associations of activated mitogen-activated protein kianse and Akt pathways in glioblastoma. Clin Cancer Res 2006; 12: 3935-41.
29. Kunishio K, Okada M, Matsumoto Y, Nagao S,. Matrix metalloproteinase-2 and -9 expression in astrocytic tumors. Brain Tumor Pathol 2003; 20: 39-45.
30. Wild-Bode C, Weller M, Wick W,. Molecular determinants of glioma cell migration and invasion. J Neurosurg 2001; 94: 978-84.
31. Au CM, Luk SK, Jackson CJ, Ng HK, Yow CM, To SS,. Differential effects of photofrin, 5-aminolevulinic acid and calphostin C on glioma cell. J Photochem Photobiol B 2006; 85: 92-101.
32. VanMeter TE, Rooprai HK, Kibble MM, Fillmore HL, Broaddus WC, Pilkington GJ,. The role of matrix metalloproteinase genes in glioma invasion: co-dependent and interactive proteolysis. J Neurooncol 2001; 53: 213-35.
33. Dai B, Kang SH, Gong W, Liu M, Aldape KD, Sawaya R, Huang S,. Aberrant FoxM1B expression increases matrix metalloproteinase-2 transcription and enhances the invasion of glioma cell. Oncogene 2007; 26: 6212-9.
34. McClung HM, Thomas SL, Osenkowski P, Toth M, Menon P, Raz A, Fridman R, Rempel SA,. SPARC upregulates MT1-MMP expression, MMP-2 activation, and the secretion and cleavage of galectin-3 in U87MG glioma cells. Neurosci Lett 2007; 419: 172-7.
35. Park MH, Ahn BH, Hong YK, Min DS,. Overexpression of phospholipase D enhances matrix metalloproteinase-2 expression and glioma cell invasion via protein kinase C and protein kianse A/NF-κB/Sp1-mediated signaling pathways. Carcinogenesis 2009; 30: 356-65.
36. Bigg HF, Wait R, Rowan AD, Cawston TE,. The mammalian chitinase-like lectin, YKL-40, binds specifically to type I collagen and modulates the rate of type I collagen fibril formation. J Biol Chem 2006; 281: 21082-95.
37. Fusetti F, Pijning T, Kalk KH, Bos E, Dijkstra BW,. Crystal structure and carbohydrate-binding properties of the human cartilage glycoprotein-39. J Biol Chem 2003; 278: 27753-60.
38. Houston DR, Tecklies AD, Krupa JC, van Aalten DM,. Structure and ligand-induced conformational change of the 39-kDa glycoprotein from human articular chondrocytes. J Biol Chem 2003; 278: 30206-12.
39. Olson MF, Sahai E,. The actin cytoskeleton in cancer cell motility. Clin Exp Metastasis 2009; 26: 273-87.
40. Gillespie GY, Soroceanu L, Manning TJ, Jr, Gladson CL, Rosenfeld SS,. Glioma migration can be blocked by non-toxic inhibitors of myosin II. Cancer Res 1999; 59: 2076-82.
41. Beadle C, Assanah MC, Monzo P, Vallee R, Rosenfeld SS, Canoll P,. The role of myosin II in glioma invasion of the brain. Mol Biol Cell 2008; 19: 3357-68.